Houte Hans Van Sells 2,388 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 2,388 shares of the business’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $16.65, for a total value of $39,760.20. Following the completion of the transaction, the chief financial officer directly owned 51,647 shares of the company’s stock, valued at approximately $859,922.55. This trade represents a 4.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Houte Hans Van also recently made the following trade(s):

• On Friday, January 30th, Houte Hans Van sold 3,661 shares of Nurix Therapeutics stock. The shares were sold at an average price of $16.60, for a total value of $60,772.60.

Nurix Therapeutics Stock Up 0.5%

Shares of NRIX stock traded up $0.09 on Thursday, hitting $16.70. The company had a trading volume of 840,236 shares, compared to its average volume of 1,138,983. The firm has a market cap of $1.73 billion, a P/E ratio of -5.28 and a beta of 1.97. The company has a 50-day moving average price of $15.82 and a 200-day moving average price of $15.99. Nurix Therapeutics, Inc. has a twelve month low of $8.19 and a twelve month high of $22.50.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings results on Wednesday, April 8th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%.The firm had revenue of $6.25 million for the quarter, compared to analysts’ expectations of $14.25 million. Equities research analysts expect that Nurix Therapeutics, Inc. will post -2.92 EPS for the current year.

Analyst Ratings Changes

NRIX has been the topic of a number of analyst reports. Stifel Nicolaus raised their target price on Nurix Therapeutics from $33.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Wells Fargo & Company dropped their price objective on Nurix Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a report on Thursday, April 9th. BTIG Research restated a “buy” rating and issued a $30.00 price objective on shares of Nurix Therapeutics in a research report on Thursday, January 29th. Morgan Stanley set a $36.00 target price on Nurix Therapeutics and gave the stock an “overweight” rating in a research note on Thursday, January 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $30.46.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Larson Financial Group LLC lifted its stake in Nurix Therapeutics by 339.0% in the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after buying an additional 1,190 shares in the last quarter. Intesa Sanpaolo Wealth Management purchased a new position in Nurix Therapeutics in the 4th quarter valued at about $31,000. Caitong International Asset Management Co. Ltd purchased a new position in Nurix Therapeutics in the 4th quarter valued at about $33,000. Wexford Capital LP purchased a new position in Nurix Therapeutics in the 3rd quarter valued at about $41,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Nurix Therapeutics by 66.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,926 shares of the company’s stock valued at $93,000 after buying an additional 1,970 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.